Dienogest in the treatment of endometriosis

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 13, 2014, Pages 1889-1902

  Bizzarri, Nicolò ^a   Remorgida, Valentino ^a   Leone Roberti Maggiore, Umberto ^b   Scala, Carolina ^a   Tafi, Emanuela ^a   Ghirardi, Valentina ^a   Salvatore, Stefano ^b   Candiani, Massimo ^b   Venturini, Pier Luigi ^a   Ferrero, Simone ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Dienogest; Efficacy; Endometriosis; Hormonal; Pharmacokinetics; Progestin; Safety

Indexed keywords

DIENOGEST; GESTAGEN; NANDROLONE;

ANALOGS AND DERIVATIVES; CLINICAL TRIAL (TOPIC); ENDOMETRIOSIS; FEMALE; HUMAN; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; CLINICAL TRIALS AS TOPIC; ENDOMETRIOSIS; FEMALE; HUMANS; NANDROLONE; PROGESTINS;

EID: 84905869200     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.943734     Document Type: Article

References (65)

1. Giudice LC, Kao LC. Endometriosis. Lancet 2004;364(9447):1789-99
2. Ferrero S, Esposito F, Abbamonte LH, et al. Quality of sex life in women with endometriosis and deep dyspareunia. Fertil Steril 2005;83:573-9
3. Gao X, Yeh YC, Outley J, et al. Health-related quality of life burden of women with endometriosis: a literature review. Curr Med Res Opin 2006;22:1787-97
4. Fourquet J, Gao X, Zavala D, et al. Patients' report on how endometriosis affects health, work, and daily life. Fertil Steril 2010;93:2424-242
5. Ferrero S, Remorgida V, Venturini PL. Current pharmacotherapy for endometriosis. Expert Opin Pharmacother 2010;11:1123-34
6. Vercellini P, Carmignani L, Rubino T, et al. Surgery for deep endometriosis: a pathogenesis-oriented approach. Gynecol Obstet Invest 2009;68:88-103
7. Brown J, Pan A, Hart RJ. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev 2010(12):CD008475
8. Johnson NP, Hummelshoj L; World Endometriosis Society Montpellier Consortium. Consensus on current management of endometriosis. Hum Reprod 2013;28:1552-68
9. Vercellini P, Somigliana E, Viganò P, et al. Endometriosis: current therapies and new pharmacological developments. Drugs 2009;69:649-75
10. Streuli I, de Ziegler D, Santulli P, et al. An update on the pharmacological management of endometriosis. Expert Opin Pharmacother 2013;14(3):291-305
11. Vercellini P, Somigliana E, Consonni D, et al. Surgical versus medical treatment for endometriosis-associated severe deep dyspareunia: I. Effect on pain during intercourse and patient satisfaction. Hum Reprod 2012;27:3450-9
12. Jeng CJ, Chuang L, Shen J. A comparison of progestogens or oral contraceptives and gonadotropin-releasing hormone agonists for the treatment of endometriosis: a systematic review. Expert Opin Pharmacother 2014;15(6):767-73
13. Ferrero S, Camerini G, Ragni N, et al. Norethisterone acetate in the treatment of colorectal endometriosis: a pilot study. Hum Reprod 2010;25(1):94-100
14. Muneyyirci-Delale O, Anopa J, Charles C, et al. Medical management of recurrent endometrioma with long-term norethindrone acetate. Int J Womens Health 2012;4:149-54
15. Vercellini P, Pietropaolo G, De Giorgi O, et al. Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate. Fertil Steril 2005;84(5):1375-87
16. Ferrero S, Leone Roberti Maggiore U, Scala C, et al. Changes in the size of rectovaginal endometriotic nodules infiltrating the rectum during hormonal therapies. Arch Gynecol Obstet 2013;287(3):447-53
17. Vercellini P, Viganò P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol 2014;10(5):261-75
18. Oettel M, Bervoas-Martin S, Elger W, et al. A 19-norprogestin without a 17alfa-ethinyl group II: dienogest from a pharmadynamic point of view. Drugs Today 1995;31:517-36
19. Oettel M, Breitbarth H, Elger W, et al. The pharamacological profile of dienogest. Eur J Contracept Reprod Health Care 1999;4:2-13
20. Foster RH, Wilde MI. Dienogest. Drugs 1998;56:825-33
21. Sasagawa S, Shimizu Y, Kami H, et al. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. Steroids 2008;73:222-31
22. Medicines Evaluation Board (Netherlands). Public assessment report of the Medicines Evaluation Board in the Netherlands: Visanne (dienogest), tablets, 2mg. 2010;online Available from: http://db. cbg-meb.nl/Pars/h104058.pdf [Last accessed 11 February 2014]
23. Oettel M, Bervoas-Matin S, Elger W, et al. A 19-norprogestin without a 17alfa-ethinyl group I: dienogest from a pharmacokinetic point of view. Drugs Today 1995;31:499-516
24. Ruan X, Seeger H, Mueck AO. The pharmacology of dienogest. Maturitas 2012;71:337-44
25. McCormack PL. Dienogest: a review of its use in the treatment of endometriosis. Drugs 2010;70:2073-88
26. Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update 2006;12:169-78
27. Klipping C, Duijkers I, Faustmann TA, et al. Pharmacodynamic study of four oral dosages of dienogest. Fertil Steril 2010;94:S181
28. Moore C, Carol W, Gräser T, et al. Influence of dienogest on ovulation in young fertile women. Clin Drug Invest 1999;18:271-8
29. Klipping C, Duijkers I, Remmers A, et al. Ovulation-inhibiting effects of dienogest in a randomized, dosecontrolled pharmacodynamic trial of healthy women. J Clin Pharmacol 2012;52:1704-13
30. Köhler G, G?oretzlehner G, Rudolf K, et al. The effect of a single midcycle administration of 0.5 or 2.0 mg dienogest (17a-cyanomethyl-17a- hydroxyestra-4,9-dien-3-one) on pituitary and ovarian function: investigation for the use as a postcoital contraceptive. Exp Clin Endocrinol 1984;84:299-304
31. Strowitzki T, Marr J, Gerlinger C, et al. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod 2010;25:633-41
32. Seitz C, Gerlinger C, Faustmann T, Strowitzki T. Safety of dienogest in the long-term treatment of endometriosis: a one-year, open label, follow-up study [abstract]. Fertil Steril 2009;92:S107
33. Schindler AE, Henkel A, Christensen B, et al. Dienogest and the breast. Gynecol Endocrinol 2009;25:472-4
34. Schindler AE. Effect and safety of highdose dienogest (20 mg/day) in the treatment of women with endometriosis. Arch Gynecol Obstet 2010;282:507-14
35. Kohler G, Goretzlehner G, Brachmann K. Lipid metabolism during treatment of endometriosis with the progestin dienogest. Acta Obstet Gynecol Scand 1989;68:633-5
36. Nikschick S, Kholer G, Mnnchen E. Carbohydrate metabolism during treatment of endometriosis with the progestin dienogest. Exp Clin Endocrinol 1989;94:211-14
37. Vercellini P, Fedele L, Pietropaolo G, et al. Progestogens for endometriosis: forward to the past. Hum Reprod Update 2003;9:387-96
38. Nakamura M, Katsuki Y, Shibutani Y, Oikawa T. Dienogest, a synthetic steroid, suppresses both embryonic and tumor-cell-induced angiogenesis. Eur J Pharmacol 1999;386:33-40
39. Yamanaka K, Xu B, Suganuma I, et al. Dienogest inhibits aromatase and cyclooxygenase-2 expression and prostaglandin E2 production in human endometriotic stromal cells in spheroid culture. Fertil Steril 2012;97:477-82
40. Barbieri RL. Endometriosis and the estrogen threshold theory. Relation to surgical and medical treatment. J Reprod Med 1998;43:287-92
41. Katsuki Y, Takano Y, Futamura Y, et al. Effects of dienogest, a synthetic steroid, on experimental endometriosis in rats. Eur J Endocrinol 1998;138:216-26
42. Fisher OM, Kaufmann-Reiche U, Moeller C, Fuhrmann U. Effects of dienogest on surgically induced endometriosis in rats after repeated oral administration. Gynecol Obstet Invest 2011;72(3):145-51
43. Kohler G, Faustmann TA, Gerlinger C, et al. A dose-ranging study to determine the efficacy and safety of 1, 2, and 4mg of dienogest daily for endometriosis. Int J Gynaecol Obstet 2010;108:21-5
44. Strowitzki T, Faustmann T, Gerlinger C, Seitz C. Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol 2010;151:193-8
45. Somigliana E, Vigano P, Barbara G, Vercellini P. Treatment of endometriosisrelated pain: options and outcomes. Front Biosci 2009;1:455-65
46. Momoeda M, Taketani Y. A randomized, double-blind, multicenter, parallel, dose-response study of dienogest in patients with endometriosis [in Japanese]. Jpn Pharmacol Ther 2007;35:769-83
47. Barbieri RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol 1992;166:740-5
48. Momoeda M, Harada T, Terakawa N, et al. Long-term use of dienogest for the treatment of endometriosis. J Obstet Gynaecol Res 2009;35:1069-76
49. Strowitzki T, Marr J, Gerlinger C, et al. Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis. Int J Gynaecol Obstet 2012;117:228-33
50. Harada T, Momoeda M, Taketani Y, et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis: a randomized, doubleblind, multicenter, controlled trial. Fertil Steril 2009;91:675-81
51. Cosson M, Querleu D, Donnez J, et al. Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study. Fertil Steril 2002;77:684-92
52. Gerlinger C, Faustmann T, Hassall JJ, Seitz C. Treatment of endometriosis in different ethnic populations: a metaanalysis of two clinical trials. BMC Womens Health 2012;12:9
53. Kitawaki J, Kusuki I, Yamanaka K, Suganuma I. Maintenance therapy with dienogest following gonadotropinreleasing hormone agonist treatment for endometriosis-associated pelvic pain. Eur J Obstet Gynecol Reprod Biol 2011;157(2):212-16
54. Kohler G, Goretzlehner G, Amon I. Therapy of endometriosis with dienogest (article in German). Zentralbl Gynakol 1987;109:795-801
55. Kohler G, Goretzlehner G, Brachmann K. Lipid metabolism during treatment of endometriosis with the progestin dienogest. Acta Obstet Gynecol Scand 1989;68:633-5
56. Miyashita M, Koga K, Takamura M, et al. Dienogest reduces proliferation, aromatase expression and angiogenesis, and increases apoptosis in human endometriosis. Gynecol Endocrinol 2014. [Epub ahead of print]
57. Petraglia F, Hornung D, Seitz C, et al. Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment. Arch Gynecol Obstet 2012;285:167-73
58. Belsey EM, Machin D, d'Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction. Contraception 1986;34:253-60
59. Katsuki Y, Sasagawa S, Takano Y, et al. Animal studies on the endocrinological profile of dienogest, a novel synthetic steroid. Drugs Exp Clin Res 1997;23:45-62
60. Schindler AE, Christensen B, Henkel A, et al. High-dose pilot study with the novel progestogen dienogestin patients with endometriosis. Gynecol Endocrinol 2006;22:9-17
61. Dunselman GAJ, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis Hum Reprod. 2014;29:400-12
62. Vercellini P, Trespidi L, Colombo A, et al. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril 1993;60:75-9
63. Davis L, Kennedy SS, Moore J, et al. Oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev 2009(1):CD001019
64. Harada T, Momoeda M, Taketani Y, et al. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertil Steril 2008;90:1583-8
65. Visanne Product Monograph. 2011